Lung cancer remains the leading cause of cancer-related deaths worldwide, with treatment decisions heavily reliant on next-generation sequencing (NGS) test results. However, the complexity and variability of genetic testing data, combined with the multitude of global treatment guidelines, present significant challenges to healthcare providers—particularly in interpreting genetic information and making informed medication choices.
In response, Professor Cheng-Yu Chen and his team at Taipei Medical University Hospital have developed “GeneMedAI,” a mobile system that leverages AI technology integrated with smartphone platforms. The system automatically interprets genetic test reports and delivers real-time, personalized medication recommendations, significantly enhancing both the speed and accuracy of treatment decisions for lung cancer patients.
Integrating Global Guidelines and Local Regulations for Precision Medicine
GeneMedAI utilizes generative AI, along with optical character recognition (OCR) and natural language processing (NLP) technologies, to rapidly and automatically interpret complex genetic mutation data found in NGS reports. Through Retrieval-Augmented Generation (RAG) technology, the system extracts the latest and most relevant treatment information from sources such as the NCCN international treatment guidelines, Taiwan FDA-approved drug labels, and the National Health Insurance drug reimbursement database. The platform then employs the open-source large language model ILAMA to consolidate and analyze this data, providing highly accurate and personalized medication suggestions.
The system features three key advantages:
High Accuracy and Local Adaptability: By integrating authoritative international drug guidelines with domestic regulatory frameworks, GeneMedAI ensures that its treatment recommendations are both clinically accurate and locally applicable.
Precise Personalized Recommendations: Utilizing advanced large language models and RAG technology, the system conducts precision searches within a vector database of genetic-drug correlations, offering tailored treatment options for individual patients.
Mobile Accessibility: Free from the limitations of time and location, users can access genetic test interpretations and treatment recommendations anytime, anywhere, through their mobile devices—without relying on specific hospital information systems.
The system supports analysis of lung cancer genes covered by Taiwan’s National Health Insurance NGS reimbursement program, including EGFR, ALK, MET, among others, as well as commercially available cancer gene sequencing panels. It cross-references these results with NCCN guidelines, FDA-approved drugs, Taiwan FDA drug labels, and National Health Insurance reimbursement criteria. Preliminary tests indicate the system can deliver accurate and effective personalized medication recommendations based on a patient’s genetic mutations.
A New Era of Mobile Healthcare: Accelerating the Popularization of Precision Medicine
Professor Cheng-Yu Chen emphasized that the GeneMedAI system enables physicians to quickly and accurately identify optimal treatment strategies tailored to individual patients, effectively shortening decision-making time and significantly improving the quality of clinical decisions. In addition to helping doctors swiftly pinpoint the best treatment options, the system presents information in a clear and accessible way, fostering shared decision-making between doctors and patients. This not only enhances patient satisfaction but also improves overall quality of life.
Looking ahead, the GeneMedAI system will continue to expand its clinical applications. Plans are in place to collaborate with major hospitals and next-generation sequencing (NGS) LDT providers in Taiwan, accelerating commercialization and advancing the development of precision medicine in the biomedical industry to a new milestone.
Resource: AI結合行動裝置平台 手機可看肺癌基因檢測報告與用藥建議
